RV3-BB

BIOLOGICAL2 trials

Sponsors

Murdoch Childrens Research Institute, PATH

Conditions

Rotavirus InfectionsRotavirus Vaccine

Phase 2

A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine

CompletedNCT03483116

Murdoch Childrens Research InstituteRotavirus Infections

Start: 2018-06-15End: 2020-01-27Updated: 2023-07-10

Mixed Schedule Study of Live Oral Rotavirus Vaccines and Trivalent P2-VP8 Subunit Rotavirus Vaccine

CompletedNCT04344054

PATHRotavirus Vaccine

Start: 2021-02-22End: 2022-09-09Updated: 2022-11-29

Related Papers

Early-life gut microbiome associates with positive vaccine take and shedding in neonatal schedule of the human neonatal rotavirus vaccine RV3-BB

Nature Communications2025-04-115 citations

Neonatal rotavirus vaccine (RV3-BB) immunogenicity and safety in a neonatal and infant administration schedule in Malawi: a randomised, double-blind, four-arm parallel group dose-ranging study.

2022-01-2021 citations